Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease-Reference-Cited by-同舟云学术

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

Published:2021-05 Issue:5 Volume:74 Page:1109-1116
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Papatheodoridi Margarita^ORCID,Hiriart Jean Baptiste,Lupsor-Platon Monica,Bronte Fabrizio^ORCID,Boursier Jerome^ORCID,Elshaarawy Omar,Marra Fabio^ORCID,Thiele Maja^ORCID,Markakis Georgios^ORCID,Payance Audrey,Brodkin Edgar^ORCID,Castera Laurent,Papatheodoridis George^ORCID,Krag Aleksander^ORCID,Arena Umberto,Mueller Sebastian^ORCID,Cales Paul^ORCID,Calvaruso Vincenza^ORCID,de Ledinghen Victor,Pinzani Massimo,Tsochatzis Emmanuel A.^ORCID

Funder

Novo Nordisk Fonden

Innovationsfonden

Horizon 2020

Odense Universitetshospital

Publisher

Elsevier BV

Subject

Hepatology

Reference27 articles.

1. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension;de Franchis;J Hepatol,2015

2. Liver cirrhosis;Tsochatzis;Lancet,2014

3. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis;Castera;J Hepatol,2015

4. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy;Tsochatzis;J Hepatol,2011

5. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease;Pavlov;Cochrane Database Syst Rev,2015

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease;Journal of Clinical and Experimental Hepatology;2025-01

2. Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease;Annals of Hepatology;2024-11

3. The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease;Annals of Hepatology;2024-09

4. Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease;Alimentary Pharmacology & Therapeutics;2024-08-14

5. EASL position paper on clinical follow-up after HCV cure;Journal of Hepatology;2024-08